CymaBay Therapeutics Investor Relations Material
Latest events
Q3 2023
CymaBay Therapeutics
Q4 2023
22 Feb, 2024
Corporate Presentation
21 Dec, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from CymaBay Therapeutics Inc
Access all reports
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. It is developing seladelpar, which is in Phase IIb clinical trials for the treatment of primary biliary cholangitis (PBC) and in Phase II trials for the treatment of bile acid diarrhea; MBX-2982 that is in preclinical development stage; and MBX-8025 to treat homozygous familial hypercholesterolemia. The company was founded in 1989 and is headquartered in Newark, California.
Latest articles
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
)
Nintendo: From Game Boy and Pokémon to Switch 2 and Mario Kart
Nintendo went from card maker to cultural icon, shaping modern entertainment through hardware innovation and world-famous characters.
19 Jun 2025
)
Ron Vachris: From Forklift Driver to CEO at Costco
Ron Vachris took over as Costco CEO in 2024, following a 40-year journey from warehouse floors to the top of one of retail's most admired companies.
18 Jun 2025
Ticker symbol
CBAY
Country
🇺🇸 United States